Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QAW039 once daily for 28 days · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | QAW039 capsules once daily for 28 days |
| 2 | EXPERIMENTAL | Placebo to QAW039 capsules once daily for 28 days |
| 3 | EXPERIMENTAL | Fluticasone propionate inhaler twice daily for 28 days |
| Name | Type | Description |
|---|---|---|
| QAW039 capsules once daily for 28 days | DRUG | - |
| Placebo to QAW039 capsules once daily for 28 days | DRUG | - |
| Fluticasone propionate inhaler twice daily for 28 days | DRUG | - |
Inclusion Criteria: * Patients with a medical history of mild to moderate persistent allergic asthma. * Patients must weigh at least 45 kg to participate in the study, and must have abody mass index (BMI) of \>17 kg/m2. * Female patients must be surgically sterilized, postmenopausal or using a doub...
QAW039 is an investigational small molecule being studied for the treatment of persistent asthma. It is administered once daily for 28 days. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
The molecular target of QAW039 has not been disclosed in available information. The drug is a small molecule being evaluated for its efficacy, safety, and pharmacokinetics in patients with persistent asthma.
QAW039 is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's potential in treating persistent asthma.
QAW039 is in Phase 2 clinical development. A Phase 2 trial has been completed, which evaluated the drug's efficacy, safety, and pharmacokinetics in patients with persistent asthma. The drug remains investigational and is not yet approved.
QAW039 has been studied in one completed Phase 2 clinical trial with the identifier NCT01253603. This randomized, double-blind, controlled trial enrolled 170 participants with persistent asthma across the United States, Belgium, Germany, Romania, and South Korea.